content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Bellicum Pharmaceuticals, Inc. (BLCM)

10.27
0.23
(2.29%)
Sep 11, 4:00PM EDT
content_middle

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. Its lead product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation, and is currently being evaluated in multiple P1/2 clinical trials. A second clinical product candidate, BPX-201, is a dendritic cell cancer vaccine in a P1 clinical trial for the treatment of metastatic castrate-resistant prostate cancer, targeting the prostate-specific membrane antigen, or PSMA.  BLCM is also focused on developing next-generation chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies, and is planning to advance several product candidates into human clinical trials, including BPX-401, a CAR T product candidate for hematological cancers that express the CD19 antigen; BPX-601, a CAR T product candidate for solid tumors overexpressing the prostate stem cell antigen, or PSCA; and BPX-701, a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma, or PRAME.

Previous Close: 
10.04
Open: 
10.20
Bid: 
10.10
Ask: 
10.39
1yr Target Price: 
24.29
Day's Range: 
9.90 - 10.34
52wk Range: 
7.41 - 23.11
Volume: 
623983
Average Daily Volume: 
839292
Market Capitalization: 
341.23M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
33226000M